 Amryt Pharma has had its price target of US40 and buy rating reiterated by Canaccord after the company hosted a virtual capital markets day. Opinion leaders spoke on the near-term growth opportunities with Filsuvez in epidermolysis bullosa EB and Mycapssa in acromegaly, said the broker, which has underlined its optimistic view. 